Redeye: Medivir Q1 2024 - Another TTP Improvement
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time to progression for fostrox, now at 7 months. The way forward with the planned phase IIb study has also been updated after a type C meeting with the FDA.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/